HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells
Sign Up to like & getrecommendations! Published in 2020 at "Acta Pharmacologica Sinica"
DOI: 10.1038/s41401-020-0399-1
Abstract: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, remains a major challenge in the targeted therapy of non-small cell lung cancer (NSCLC). HKB99 is a novel allosteric inhibitor of… read more here.
Keywords: allosteric inhibitor; inhibitor; erlotinib resistant; invasive pseudopodia ... See more keywords